KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model[1].
KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models[1].
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I[1].
KA2507 exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg)[1].
| Animal Model: | Male C57BL/6 mice, B16-F10 melanoma model[1] |
| Dosage: | 100 mg/kg, 200 mg/kg, 200 mg/kg |
| Administration: | Oral gavage, daily, for 20 days |
| Result: | Demonstrated antitumor efficacy. |
| Animal Model: | Male C57BL/6 mice[1] |
| Dosage: | 200 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral administration |
| Result: | Oral bioavailability (15%), Cmax (300 ng/mL). |
![Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy- Structure](/CAS/20210305/GIF/1636894-46-6.gif)
